Ikarian Capital, LLC: 13F holdings, Q2 2026
Hedge fund · SEC EDGAR filings (CIK 1778253) · Explore on the interactive board
Ikarian Capital, LLC disclosed 126 US equity positions worth $610.9m in its Q2 2026 13F filing (holdings as of June 30, 2026, filed August 14, 2026). Its largest position is ABVX at 7.1% of the reported book, followed by KOD, ALMS. The top ten holdings are 39.5% of the book, and the portfolio behaves like about 40 equal-weight positions. Versus the prior filing it opened 27 new positions, added to 18, reduced 29 and exited 25. Note: this manager's most recent filing is 3934 quarters behind the newest quarter on file, so these figures are history rather than current positioning.
What does Ikarian Capital, LLC own? Top holdings as of June 30, 2026
Change is measured in shares against the previous filing (Q1 2026), so price moves do not read as decisions. This quarter: 27 new, 18 added, 29 reduced, 25 exited.
| # | Stock | Sector | Weight | Value | Shares | Δ shares | Action |
|---|---|---|---|---|---|---|---|
| 1 | ABVX ABIVAX SA | Healthcare | 7.1% | $43.4m | 328,635 | 470% | added |
| 2 | KOD KODIAK SCIENCES INC | Healthcare | 6.8% | $41.3m | 1,059,730 | -16% | reduced |
| 3 | ALMS ALUMIS INC | Healthcare | 4.0% | $24.5m | 870,548 | -28% | reduced |
| 4 | PRAX PRAXIS PRECISION MEDICINES I | Healthcare | 4.0% | $24.4m | 72,842 | 2% | added |
| 5 | PCVX VAXCYTE INC | Healthcare | 3.7% | $22.6m | 388,682 | -9% | reduced |
| 6 | ANIP ANI PHARMACEUTICALS INC | Healthcare | 3.7% | $22.5m | 272,085 | 85% | added |
| 7 | CLDX CELLDEX THERAPEUTICS INC NEW | Healthcare | 2.9% | $17.8m | 478,500 | 4% | added |
| 8 | RCUS ARCUS BIOSCIENCES INC | Healthcare | 2.5% | $15.6m | 504,559 | – | new |
| 9 | RLMD RELMADA THERAPEUTICS INC | Healthcare | 2.4% | $14.9m | 2,148,359 | -20% | reduced |
| 10 | CAPR CAPRICOR THERAPEUTICS INC | Healthcare | 2.4% | $14.5m | 604,215 | 14% | added |
| 11 | COGT COGENT BIOSCIENCES INC | Healthcare | 2.3% | $14.3m | 370,084 | – | new |
| 12 | VERA VERA THERAPEUTICS INC | Healthcare | 2.2% | $13.3m | 310,000 | 55% | added |
| 13 | CTNM CONTINEUM THERAPEUTICS INC | 2.2% | $13.2m | 807,874 | 0% | held | |
| 14 | TENX TENAX THERAPEUTICS INC | 1.9% | $11.5m | 787,600 | -23% | reduced | |
| 15 | CCCC C4 THERAPEUTICS INC | Healthcare | 1.9% | $11.4m | 2,433,000 | – | new |
| 16 | MAZE MAZE THERAPEUTICS INC | Healthcare | 1.9% | $11.3m | 378,999 | 0% | held |
| 17 | BHVN BIOHAVEN LTD | Healthcare | 1.8% | $11.1m | 748,181 | 81% | added |
| 18 | CNTB CONNECT BIOPHARMA HLDGS LTD | 1.8% | $10.8m | 4,538,534 | -16% | reduced | |
| 19 | ANRO ALTO NEUROSCIENCE INC | Healthcare | 1.8% | $10.7m | 407,338 | -21% | reduced |
| 20 | PHVS PHARVARIS N V | Healthcare | 1.7% | $10.7m | 308,856 | -37% | reduced |
| 21 | JBIO JADE BIOSCIENCES INC | Healthcare | 1.6% | $9.5m | 427,349 | -17% | reduced |
| 22 | DMRA DAMORA THERAPEUTICS INC | Healthcare | 1.4% | $8.7m | 335,710 | 0% | held |
| 23 | VRDN VIRIDIAN THERAPEUTICS INC | Healthcare | 1.3% | $7.8m | 425,000 | – | new |
| 24 | PELTHOS THERAPEUTICS INC | 1.2% | $7.3m | 256,598 | 0% | held | |
| 25 | ZURA ZURA BIO LTD | Healthcare | 1.2% | $7.2m | 1,218,492 | 2% | added |
| 26 | TECX TECTONIC THERAPEUTIC INC | Healthcare | 1.2% | $7.1m | 205,837 | 31% | added |
| 27 | SPRB SPRUCE BIOSCIENCES INC | 1.1% | $6.6m | 121,356 | 0% | held | |
| 28 | HIMS HIMS & HERS HEALTH INC | Healthcare | 1.1% | $6.5m | 188,381 | – | new |
| 29 | ELVN ENLIVEN THERAPEUTICS INC | Healthcare | 1.1% | $6.4m | 126,541 | – | new |
| 30 | PROQR THRAPEUTICS N V | 1.0% | $6.4m | 3,425,930 | 130% | added | |
| 31 | DRUG BRIGHT MINDS BIOSCIENCES INC | Healthcare | 1.0% | $6.2m | 88,951 | -47% | reduced |
| 32 | OVID OVID THERAPEUTICS INC | Healthcare | 1.0% | $6.1m | 2,269,704 | -22% | reduced |
| 33 | OCGN OCUGEN INC | Healthcare | 1.0% | $6.1m | 3,962,972 | 0% | held |
| 34 | ALPHA COGNITION INC | 1.0% | $6.0m | 836,259 | -21% | reduced | |
| 35 | HROW HARROW INC | 0.9% | $5.8m | 135,775 | -75% | reduced | |
| 36 | KZIA KAZIA THERAPEUTICS LTD | 0.9% | $5.6m | 396,201 | – | new | |
| 37 | RARE ULTRAGENYX PHARMACEUTICAL IN | Healthcare | 0.9% | $5.5m | 165,617 | -66% | reduced |
| 38 | QTTB Q32 BIO INC | 0.9% | $5.5m | 430,000 | – | new | |
| 39 | EPRX EUPRAXIA PHARMACEUTICALS INC | 0.9% | $5.4m | 809,741 | -33% | reduced | |
| 40 | BIOA BIOAGE LABS INC | 0.8% | $4.9m | 200,000 | – | new | |
| 41 | RZLT REZOLUTE INC | 0.8% | $4.9m | 935,012 | 5574% | added | |
| 42 | OLMA OLEMA PHARMACEUTICALS INC | Healthcare | 0.8% | $4.8m | 383,281 | -36% | reduced |
| 43 | MNPR MONOPAR THERAPEUTICS INC | 0.7% | $4.4m | 47,861 | – | new | |
| 44 | BBIO BRIDGEBIO PHARMA INC | Healthcare | 0.7% | $4.3m | 57,417 | -64% | reduced |
| 45 | IVA INVENTIVA SA | 0.7% | $4.2m | 1,129,101 | -21% | reduced | |
| 46 | ABSI ABSCI CORPORATION | Healthcare | 0.7% | $4.1m | 353,772 | – | new |
| 47 | ALEC ALECTOR INC | Healthcare | 0.7% | $4.0m | 1,982,606 | -5% | reduced |
| 48 | CLYM CLIMB BIO INC | Healthcare | 0.6% | $3.9m | 300,000 | – | new |
| 49 | FULC FULCRUM THERAPEUTICS INC | Healthcare | 0.6% | $3.8m | 1,049,161 | 0% | held |
| 50 | CRDL CARDIOL THERAPEUTICS INC | 0.6% | $3.5m | 3,325,000 | 22% | added |
What did Ikarian Capital, LLC sell? Positions exited since the previous filing
| Stock | Prior weight | Prior value |
|---|---|---|
| 430 TERNS PHARMACEUTICALS INC | 42.3% | $76.8m |
| CYTK CYTOKINETICS INC | 10.3% | $18.7m |
| RVMD REVOLUTION MEDICINES INC | 8.7% | $15.9m |
| ORKA ORUKA THERAPEUTICS INC | 6.5% | $11.9m |
| SLNOEUR SOLENO THERAPEUTICS INC | 6.3% | $11.5m |
| PVLA PALVELLA THERAPEUTICS INC NE | 4.4% | $8.1m |
| LLY ELI LILLY & CO | 3.3% | $6.0m |
| SRZN SURROZEN INC | 2.8% | $5.0m |
| LEGN LEGEND BIOTECH CORP | 2.3% | $4.1m |
| KPTI KARYOPHARM THERAPEUTICS INC | 2.3% | $4.1m |
| PERCEPTIVE CAP SOLUTIONS COR | 1.5% | $2.6m |
| VIR VIR BIOTECHNOLOGY INC | 1.4% | $2.6m |
| BBOT BRIDGEBIO ONCOLOGY THERAPEUT | 1.3% | $2.4m |
| NUVALENT INC | 1.3% | $2.4m |
| JAZZ JAZZ PHARMACEUTICALS PLC | 1.3% | $2.4m |
| UNIQURE NV | 0.8% | $1.5m |
| DFTX DEFINIUM THERAPEUTICS INC | 0.6% | $1.1m |
| 2KZ0 KEZAR LIFE SCIENCES INC | 0.4% | $758.4k |
| IMUX IMMUNIC INC | 0.4% | $748.9k |
| CNTA CENTESSA PHARMACEUTICALS PLC | 0.4% | $719.4k |
| 4XC1 KALVISTA PHARMACEUTICALS INC | 0.4% | $706.9k |
| INSM INSMED INC | 0.4% | $689.1k |
| SGMOQ SANGAMO THERAPEUTICS INC | 0.2% | $300.9k |
| VERU VERU INC | 0.2% | $295.1k |
| IOBTQ IO BIOTECH INC | 0.0% | $81.4k |
Sector mix
| Sector | Weight |
|---|---|
| Healthcare | 75.8% |
| Financial Services | 0.0% |
Sectors cover positions whose ticker resolved to a sector; the remainder is unclassified, not cash.
Filing history
How concentrated is Ikarian Capital, LLC's portfolio?
Across every quarter Ikarian Capital, LLC has filed, its median largest position is 9.0% of the book and its median top-ten weight is 40.4%, which WhaleCreep classifies as concentrated (the gate is a median largest position of 5%). Of 27.0 completed holding spells, the median lasted 1.0 quarters; 126.0 positions are still open and their final length is unknown.